FormFactor has been upgraded from Buy to Strong Buy with a price target of $134, indicating a 27% upside from its current price of $105. The upgrade is driven by expected growth in high-bandwidth memory (HBM) test complexity, increased demand for GPU and networking probe cards, adoption of co-packaged optics, and operational efficiencies from ramping up manufacturing at Farmers Branch. Risks include potential slowdowns in HBM or AI infrastructure, delays in manufacturing, and slower adoption of co-packaged optics. The price target is based on a 40x forward non-GAAP P/E multiple applied to the 2028 earnings estimate.
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
